Vivio Glogal Inoustries Ltd.
(A Govt. of India recognised 'Star Export House')

023-CB-QMS

ISO 9001:2015
Contact Address For Correspondence :
C/o. Sumichem Corporation, 1-D, Dhannur Bldg.,
Sir P. M. Road, Fort, Mumbai - 400001, India
Tel.: (91) 22-22619531 / 22619550 URL : www.vividglobalinds.com
Email : info@vividglobalinds.com
Date: 27/10/2023
To,
The Manager
Listing Department,
Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street, Fort,

Mumbai - 400001

Scrip Code: 524576
Kind Attn: Listing Department / Department of Corporate Affairs.
Sub: Outcome of the Board Meeting held on 27.10.2023

Dear Sir,
The Board of Directors in its meeting held on Friday, 27.10.2023 at 04:00 p.m., interalia, approved the Un-Audited Financial results along with Limited Review Report for the quarter and half year ended $30^{\text {th }}$ September, 2023.

Kindly take the above in your record and acknowledge receipt of the same.
The Board meeting concluded at $5.00 \mathrm{p} . \mathrm{m}$.

Thanking You.
Yours Faithfully,
For Vivid Global Industries Limited


Sumish Sudhir Mody
Managing Director
DIN: 00318652

Regd. Office : D-21/1, M.I.D.C. Tarapur - 401 506. Via Boisar, Dist. Palghar, Maharashtra Factory : Plot No. 143, Phase II, G.I.D.C. Ind. Estate, Vapi - 396195, Dist. Valsad, (Gujarat) (C) : (0260) 2400726
[ూM
FRN 104777 W
CHARTERED ACCOUNTANTS

## LIMITED REVIEW REPORT OF M/S VIVID GLOBAL INDUSTRIES LIMITED

We have reviewed the accompanying statement of unaudited financial results of $\mathrm{M} / \mathrm{s}$ Vivid Global Industries Limited for the period ended $30^{\text {th }}$ September 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor"of the Entity", issued by the Institute of Chartered Accountants of India.

This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.M.Kapadia and Associates


Kamlesh M. Kapadia
Mem. No.: 039707

UDIN: 23039707 BGVTIZ 7481

Date: $27^{\text {th }}$ October 2023
Place: Mumbai

VIVID GLOBAL INDUSTRIES LIMITED
CIN NO. L24100MH1987PLC043911
Regd. Office : D-21/1, MIDC Tarapur Via Boisar, Dist. Palghar, Maharashtra
Statement of Unaudited Standalone Financial Results for the Quarter and Six months ended 30th September 2023



REPORTING OF SEGMENT - WISE REVENUES \& EXPENDITURE.



Unaudited Standalone Balance Sheet as on 30th September 2023

|  |  |
| :--- | :--- |
| I. | ASSETS |
| 1. | NON-CURRENT ASSETS |
| (a) Property, Plant and Equipme |  |
| (b) Right of use assets |  |
| (c) Capital Work-in-Progress |  |
| (d) Investment Properties |  |
| (e) Goodwill |  |
| (f) Other Intangible Assets |  |
| (g) Intangible Assets Under Dev |  |
| (h) Biological Assets Other Than |  |
| (i) Financial Assets |  |
| (i) Investments |  |
| (ii) Trade receivables |  |
| (iii) Loans |  |
| (iv) Other Financial Assets |  |

(j) Deferred Tax Assets (Net)
(k) Other Non-current Assets

## SUB-TOTAL

2. CURRENT ASSETS
(a) Inventories
(b) Financial Assets
(i) Investments
(ii) Trade Receivables
(iii) Cash and Cash Equivalents
(iv) Bank Balances other than (iii) above
(v) Loans
(vi) Other Financial Assets
(c) Other Current Assets

SUB-TOTAL
TOTAL ASSETS
II. EQUITY AND LIABILITIES

1. EQUITY
(a) Equity share capital
(b) Other equity
2. LIABILITIES

NON-CURRENT LIABILITIES
(a) Financial liabilities
(i) Borrowings
(ii) Trade Payable
(iii) Other financial liabilities
(b) Provisions
(c) Deferred Tax Liabilities (net)
(d) Other non current liabilities

## SUB-TOTAL

## CURRENT LIABILITIES

(a) Financial liabilities
(i) Borrowings
(ii) Trade payables
(iii) Other financial liabilities
(b) Provisions
(c) Other current liabilities
(d) Current tax liabilities (net)

## SUB-TOTAL



| Particulars | For the Half Year <br> Ended 30th <br> September 2023 | ```For the Year ended 31st March 2023``` | For the Half Year <br> Ended 30th <br> September 2022 |
| :---: | :---: | :---: | :---: |
| A Cash flows from operating activities |  |  |  |
| Profit before tax from continuing operations | 7.64 | (2.93) | (28.17) |
| Profit before tax from discontinuing operations | - | - | - |
|  | 7.64 | (2.93) | (28.17) |
| Adjustments for |  |  |  |
| Depreciation and amortisation expense | 39.57 | 78.10 | 38.97 |
| Finance costs | 18.65 | 31.19 | 30.99 |
| Interest income | - | - | - |
| Dividend income | - | - | - |
| Provision for employee benefits expense | - | - | - |
| Provision for doubtful debts and advances/bad debts written off/(back) | - | - | - |
| Provision for contingencies (net) | - | - | - |
| Provision for exceptional items | - | - | - |
| Foreign exchange gain (net) | - | - | - |
| (Profit)/ loss on assets sold or discarded (net) | - | - | - |
| Difference in interim dividend adjusted | - | - | - |
|  | - | - | - |
| Operating profit before working capital changesAdjustments for | 65.86 | 106.37 | 41.78 |
|  | Adjustments for |  |  |
| Trade receivables, other financial assets and other assets | 572.51 | 211.16 | 136.88 |
| Inventories | (51.80) | (60.29) | 52.28 |
| Trade payables, other financial liabilities and other liabilities | (646.69) | (40.93) | 379.16 |
| Cash generated from operations | (60.11) | 216.31 | 610.11 |
| Taxes paid (net of refund) | (2.29) | (5.97) | - |
| Proposed Dividend | - | - | - |
| Net cash generated from operating activities | (62.40) | 210.34 | 610.11 |
| B Cash flows from investing activities |  |  |  |
| Acquisition of property, plant and equipment (including capital work-in-progress) | (4.16) | (20.29) | (5.54) |
| Acquisition of intangible assets (including intangible asset under development) | - | - | - |
| Proceeds from sale of property, plant and equipment | - | - | - |
| Proceeds from sale of other non-current investments | - | - | - |
| Proceeds from sale of current investments | - | - | - |
| Purchase of current investments | - | - | - |
| Investment in subsidiary * | - | . - | - |
| Bank balances not considered as cash and cash equivalent | - | - | - |
| Payment on acquisition of business | - | - | - |
| (Payment on)/ proceeds from sale of discontinued operations | - | - | - |
| Interest received | - | - | - |
| Dividend received | - | - | - |
| Net cash used in investing activities | (4.16) | (20.29) | (5.54) |
| C Cash flows from financing activities |  |  |  |
| Proceeds from borrowings | 111.18 | 5.09 | 23.21 |
| Repayment of borrowings | (9.12) | (208.75) | (121.86) |
| Repayment towards lease liabilities | (1.04) | - | (20.82) |
| Finance costs paid | (18.65) | (31.19) | (30.99) |
| Bank balances in dividend and restricted account | - | - | ${ }^{7}$ - |
| Reduction in Dividend Paid for FY 2018-19 | - | - | - |
| Dividends paid including distribution tax | - | - | - |
| Net cash used in financing activities | 82.37 | (234.85) | (150.45) |
| Net decrease in cash and cash equivalents | 15.80 | (44.80) | 454.12 |
| Cash and cash equivalents at the Beginning of the Period Exchange difference on translation of foreign currency cash and cash equivalents <br> Movement in cash and cash equivalents pertaining to discontinued operations <br> Cash and cash equivalents at the End of the Period | 302.92 | 347.72 | 347.72 |
|  | - | - | - |
|  | 318.72 | 302.92 | 801.84 |
|  |  |  |  |

1 Total comprehensive income reconciliation

| Particulars | Quarter Ended |  |  | Half Year Ended |  | Year Ended |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 30th September 2023 | 30th June 2023 | 30th September 2022 | 30th September 2023 | 30th September 2022 | 31st March 2023 |
| Net Profit as per Previous GAAP | 39.02 | (33.67) | (6.10) | 5.35 | (28.17) | (18.82) |
| Fair value of investment designated at FVTPL |  |  |  |  |  |  |
| Employee Benefit Expenses |  |  |  |  |  |  |
| Revenue recognition - multiple element accounting |  |  |  |  |  |  |
| Others |  |  |  |  |  |  |
| Net profit for the period as per IND AS | 39.02 | (33.67) | (6.10) | 5.35 | (28.17) | (18.82) |
| Other Comprehensive Income |  |  |  |  |  |  |
| Total Comprehensive Income | 39.02 | (33.67) | (6.10) | 5.35 | (28.17) | (18.82) |

2 Equity Reconciliation

| Particulars | Quarter Ended |  |  | Half Year Ended |  | Year Ended |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 30th September 2023 | 30th June 2023 | 30th September 2022 | 30th September 2023 | 30th September 2022 | 31st March 2023 |
| Equity under previous GAAP | 456.44 | 456.44 | 456.44 | 456.44 | 456.44 | 456.44 |
| Fair Value of Mutual Fund |  |  |  |  |  |  |
| Taxes |  |  |  |  |  |  |
| Others |  |  |  |  |  |  |
| Equity as per Ind AS | 456.44 | 456.44 | 456.44 | 456.44 | 456.44 | 456.44 |

3 Foreign Exchange Gain/Loass

|  | Quarter Ended |  |  | Half Year Ended |  | Year Ended |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Particulars | 30th September 2023 | 30th June 2023 | 30th September 2022 | 30th September 2023 | 30th September 2022 | 31st March 2023 |
| Net Foreign Exchange (Gain)/ Loss | 4.11 | (8.73) | (2.03) | (4.62) | 12.64 | (11.84) |
| Net Foreign Exchange (Gain)/Loss arising from hedging | $\checkmark$ |  | $\checkmark$ | - | $\checkmark$ | $\checkmark$ |

4 The above results were received by the audit committee and taken on record at the meeting of the Board of Directors of the company held on $27 / 10 / 2023$.
5 The company is operating in single segment i.e Manufacturing of-Chemicals, but the Segment Reporting is done for Geographical Segment of Local Sale and Export Sales.
Figure for the corresponding period/previous year have been rearranged and regrouped wherever necessary.
7 Formula used for calculation of Ratios (Continuing operations):
a) Debt Equity Ratio = Debt $/$ Equity
(Debt: Long-term borrowings +Current maturities of long term borrowings + Short-term borrowings)
(Equity: Shareholder's Funds)
During the Quarter ended 30th September 2023, no investors' complaints were received which were redressed during the quarter itself. There was no complaint pending at the beginning
8 or at the end of the quarter.
In Segment Reporting of the Company the Unallocable Expenses \& Capital Employed figure of each segment is calculated on the proportion of Export Sales to Total Sales for the
9 corresponding period.
10 Tax Liability for the quarter under review, is under the Normal Income Tax for the Quarter ended on 30th September 2023
As per our current assessment, no significant impact on carrying amounts of inventories, goodwill, intangible assets, trade receivables, investments and other financial assets is expected,
11 and we continue to monitor changes in future economic conditions. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results.
12 Previous period's / year's figures have been regrouped or reclassified wherever necessary.

Date : 27/10/2023


